Chris Verslype
Impact in
- Hepatology top 0.05%
- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Disease and Transplantation
- Oncology top 0.2%
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Cancer Immunotherapy and Biomarkers
Papers in
- Hepatology 136
- Hepatocellular Carcinoma Treatment and Prognosis 68
- Liver Disease and Transplantation 36
- Epidemiology 107
- Neuroendocrine Tumor Research Advances 47
- Liver Disease Diagnosis and Treatment 43
- Co-authors
- Eric Van Cutsem (73 shared papers)Yves Humblet (5 shared papers)Frederik Nevens (95 shared papers)Ian Chau (3 shared papers)David Khayat (3 shared papers)Andreas Harstrick (1 shared paper)Harry Bleiberg (2 shared papers)David Cunningham (1 shared paper)
- Journals
- Annals of Oncology (26 papers)Journal of Hepatology (25 papers)European Journal of Gastroenterology & Hepatology (9 papers)Hepatology (9 papers)Journal of Vascular and Interventional Radiology (7 papers)
- Partner nations
- BelgiumUnited StatesGermany
In The Last Decade
Chris Verslype
340 papers receiving 20.8k citations
Chris Verslype's Hit Papers
Peers
Comparison fields: 5 of 156
- Hepatology 7.3k
- Oncology 7.8k
- Cancer Research 2.4k
- Pulmonary and Respiratory Medicine 3.5k
- Epidemiology 3.6k
Countries citing papers authored by Chris Verslype
This map shows the geographic impact of Chris Verslype's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chris Verslype with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chris Verslype more than expected).
Fields of papers citing papers by Chris Verslype
This network shows the impact of papers produced by Chris Verslype. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chris Verslype. The network helps show where Chris Verslype may publish in the future.
Co-authors
The 25 scholars most cited alongside Chris Verslype, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 352 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer Hit paper breakdown → | 2004 | 4215 |
| 2 | Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial Hit paper breakdown → | 2018 | 2076 |
| 3 | Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2018 | 827 |
| 4 | Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2023 | 699 |
| 5 | 2004 | 658 | |
| 6 | 2009 | 558 | |
| 7 | Evidence for an alternative fatty acid desaturation pathway increasing cancer plasticity Hit paper breakdown → | 2019 | 398 |
| 8 | 2003 | 381 | |
| 9 | 2006 | 364 | |
| 10 | Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines Hit paper breakdown → | 2021 | 359 |
| 11 | 2012 | 323 | |
| 12 | 2008 | 312 | |
| 13 | 2010 | 308 | |
| 14 | Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma Hit paper breakdown → | 2019 | 291 |
| 15 | 2007 | 277 | |
| 16 | 2012 | 277 | |
| 17 | 2018 | 258 | |
| 18 | 2013 | 237 | |
| 19 | 2006 | 226 | |
| 20 | 2010 | 217 |
About Chris Verslype
Chris Verslype is a scholar working on Hepatology, Epidemiology, Oncology, Surgery and Cancer Research, having authored 352 papers that have together received 21.4k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (68 papers), Neuroendocrine Tumor Research Advances (47 papers), Liver Disease Diagnosis and Treatment (43 papers), Liver Disease and Transplantation (36 papers), Pancreatic and Hepatic Oncology Research (29 papers), Lung Cancer Research Studies (28 papers), Neuroblastoma Research and Treatments (22 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (21 papers). The work is most often cited by research in Hepatology (7.3k citations), Oncology (7.8k citations), Cancer Research (2.4k citations), Pulmonary and Respiratory Medicine (3.5k citations) and Epidemiology (3.6k citations). Chris Verslype has collaborated with scholars based in Belgium, United States and Germany. Frequent co-authors include Eric Van Cutsem, Yves Humblet, Frederik Nevens, Ian Chau, David Khayat, Andreas Harstrick, Harry Bleiberg, David Cunningham, Matthias Mueser and Salvatore Siena. Their work appears in journals such as Annals of Oncology, Journal of Hepatology, European Journal of Gastroenterology & Hepatology, Hepatology and Journal of Vascular and Interventional Radiology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.